Studies have also identified changes in lipid metabolism that are also present in IBD patients, which in turn could lead to the use of inflammatory lipids as a potential biomarker for IBD [143,144], where peroxisome proliferator-activated receptor gamma (PPAR-γ) could serve as a key conjugate of lipids with innate immunity [145,146]. The gene discussed is PPARG; the disease is inflammatory bowel disease.